粒子線治療市場：タイプ（陽子線治療、重粒子線治療）、製品（サイクロトロン、シンクロトロン、シンクロサイクロトロン）、サービス、システム（シングルルーム、マルチルーム）、がんタイプ（小児、前立腺）、用途（治療、研究）別 - 2027年までの世界予測

Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2027

MarketsandMarketsは、粒子線治療市場は2022年の6億7700万米ドルから2027年には10億400万米ドルに達し、2022年から2027年にかけて年平均成長率8.2％で成長すると予測しています。市場成長の背景には、世界的なが... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年5月28日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	203	214	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

MarketsandMarketsは、粒子線治療市場は2022年の6億7700万米ドルから2027年には10億400万米ドルに達し、2022年から2027年にかけて年平均成長率8.2％で成長すると予測しています。市場成長の背景には、世界的ながん罹患率の増加によるさまざまな利点、光子療法に対する粒子療法の利点、臨床試験における粒子療法の受け入れ拡大、世界的な粒子療法センターの増加といった要因があります。しかし、治療費の手頃さとアクセス性、インフラ整備が、今後数年間の市場成長をある程度制限することが予想されます。
本レポートでは、粒子線治療市場を、タイプ、製品・サービス、がん種、用途、がん種、地域に基づいて区分しています。
"粒子線治療市場のアプリケーションタイプ別では、治療アプリケーションが最大のシェアを占めた"
粒子線治療市場は、用途に基づき、治療用途と研究用途に区分されています。2021年には、治療用途セグメントが粒子線治療市場の94.4%という圧倒的なシェアを占めると予測されます。病院に新しく高度な放射線治療システムを装備またはアップグレードすることを目的とした政府のイニシアチブの増加。

"粒子線治療市場のタイプ別では陽子線治療が最大シェアを占める"

粒子線治療市場は、タイプ別に陽子線治療と重粒子線治療に区分されます。2021年には陽子線治療が最大のシェア（85.7％）を占めると予想されています。従来のX線を用いた光子療法と比較して、高線量、治療時間の短縮、高精度、副作用の低減などの要因が挙げられます。

"製品別では、サイクロトロンが粒子線サーピィ市場で最大のシェアを占めている"

製品に基づき、粒子線治療製品市場はさらにサイクロトロン、シンクロトロン、シンクロサイクロトロンに区分されます。2021年には、サイクロトロンセグメントが粒子線治療市場の71.4%のシェアを占めると予想され、このセグメントは予測期間中にCAGR 6.7%で成長すると予測されています。サイクロトロンが他の加速器と比較して提供する利点と、技術的に高度なシステムの開発が、この市場セグメントの発展を後押しする主な要因となっています。

"粒子線治療市場の地域別シェアはアジア太平洋地域が最多"
アジア太平洋地域は、2021年に最大の市場シェアを占めると予想され、また予測期間中に最も高い成長率を示すと予測されています。アジア太平洋地域は、アジア太平洋諸国における医療費の増加や高度な粒子線治療技術の利用を促進する取り組みの高まりにより、粒子線治療市場で活動するプレイヤーに大きな成長機会を提供すると期待されています。

主要市場プレイヤー:
粒子線治療市場における主なプレイヤーは、IBA Worldwide（EU）、Hitachi, Ltd. （日本）、Varian Medical Systems, Inc.(日本）、Varian Medical Systems, Inc.（米国）、Provision Healthcare, LLC（米国）、Optivus Proton Therapy, Inc.（米国）、Protom International, Inc.（米国）などがあります。
本レポートで参照した粒子線治療市場の主要参入企業（供給側）の内訳は以下の通りである。
- 企業タイプ別ティア1～5％、ティア2～15％、ティア3～80％。
- 役職別Cレベル-45%, ディレクターレベル-25%, その他-30
- 地域別北米-36％、欧州-26％、アジア太平洋-21％、中南米-10％、中近東・アフリカ-7
調査対象範囲
この市場調査は、様々なセグメントにわたる粒子線治療市場を対象としています。製品別、用途別、エンドユーザー別、地域別など、さまざまなセグメントにおける市場規模や成長性の推定を目的としています。また、市場の主要企業の詳細な競合分析、企業プロファイル、製品および事業の提供に関する主要な見解、最近の開発、主要な市場戦略についても記載しています。
レポート購入の主なメリット
本レポートは、この市場における市場リーダー/新規参入者を支援し、粒子線治療市場とそのセグメントの最も近い近似値に関する情報を提供します。本レポートは、利害関係者が競争環境を理解し、自社のビジネスをより良く位置づけるための洞察を得て、適切な市場参入戦略を計画するのに役立ちます。また、市場の脈動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を得る上で、利害関係者の助けとなります。

ページTOPに戻る

1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS AND EXCLUSIONS 28
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
1.3.2 MARKETS COVERED – BY REGION 29
1.3.3 YEARS CONSIDERED 29
1.4 CURRENCY 29
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 30
1.5 STAKEHOLDERS 30
1.6 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH APPROACH 32
FIGURE 1 RESEARCH DESIGN 32
2.1.1 SECONDARY DATA 32
2.1.1.1 Key data from secondary sources 33
2.1.2 PRIMARY DATA 34
2.1.2.1 Primary sources 34
2.1.2.2 Key data from primary sources 35
2.1.2.3 Breakdown of primaries 35
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE):
BY END USER TYPE, DESIGNATION, AND REGION 36
2.2 MARKET SIZE ESTIMATION 36
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2020) 37
FIGURE 5 SUPPLY SIDE ANALYSIS: PARTICLE THERAPY MARKET 38
FIGURE 6 TOP-DOWN APPROACH 39
FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022– 2027) 40
FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS (2021) 41
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 42
FIGURE 9 DATA TRIANGULATION METHODOLOGY 42
2.4 KEY INDUSTRY INSIGHTS 43
2.5 LIMITATIONS 43
2.5.1 METHODOLOGY-RELATED LIMITATIONS 43
2.6 RISK ASSESSMENT 44
2.7 STUDY ASSUMPTIONS 44
3 EXECUTIVE SUMMARY 45
FIGURE 10 PARTICLE THERAPY MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 45
FIGURE 11 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2022 VS. 2027 (USD MILLION) 46
FIGURE 12 PARTICLE THERAPY MARKET, BY PRODUCTS, 2022 VS. 2027 (USD MILLION) 46
FIGURE 13 PARTICLE THERAPY MARKET, BY SYSTEMS, 2022 VS. 2027 (USD MILLION) 47
FIGURE 14 PARTICLE THERAPY MARKET, BY CANCER TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 15 PARTICLE THERAPY MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 48
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF PARTICLE THERAPY MARKET 49
4 PREMIUM INSIGHTS 50
4.1 PARTICLE THERAPY MARKET OVERVIEW 50
FIGURE 17 INCREASING CANCER PREVALENCE TO DRIVE MARKET GROWTH 50
4.2 REGIONAL MIX: PARTICLE THERAPY MARKET 50
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 50
4.3 ASIA PACIFIC: PARTICLE THERAPY M ARKET, BY TYPE AND COUNTRY (2021) 51
FIGURE 19 PROTON THERAPY TO ACCOUNT FOR LARGEST SHARE
OF ASIA PACIFIC MARKET IN 2021 51
4.4 PARTICLE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
FIGURE 20 CHINA TO REGISTER HIGHEST REVENUE GROWTH DURING FORECAST PERIOD 52
4.5 PARTICLE THERAPY MARKET: DEVELOPED VS. DEVELOPING MARKETS 53
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH
RATE DURING FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
TABLE 2 MARKET DYNAMICS: IMPACT ANALYSIS 54
5.1.1 DRIVERS 55
5.1.1.1 Advantages offered by particle therapy over photon therapy 55
5.1.1.2 Growing global prevalence of cancer 55
5.1.1.3 Growing adoption of particle therapy in clinical trials 56
5.1.1.4 Increasing number of particle therapy centers worldwide 56
5.1.1.5 Rising technological advancements 57
5.1.2 RESTRAINTS 57
5.1.2.1 Infrastructural challenges in healthcare facilities 57
5.1.2.2 Affordability and accessibility of treatments 58
5.1.2.3 Unfavorable reimbursement policies and limited insurance coverage for particle therapy 58
5.1.3 OPPORTUNITIES 59
5.1.3.1 Growing adoption of particle therapy in emerging markets 59
5.1.3.2 Rising healthcare expenditure across developing countries 59
5.1.4 CHALLENGES 60
5.1.4.1 Difficulties in visualizing tumors during particle therapy procedures 60
5.1.4.2 Increasing risk of radiation exposure 60
5.2 COVID-19 IMPACT ON ECONOMIC SCENARIO IN PARTICLE THERAPY MARKET 60
5.3 ECOSYSTEM ANALYSIS 61
FIGURE 22 PARTICLE THERAPY MARKET: ECOSYSTEM ANALYSIS 61
5.4 PRICING ANALYSIS 62
5.5 SUPPLY CHAIN ANALYSIS 62
FIGURE 23 SUPPLY CHAIN ANALYSIS: PARTICLE THERAPY MARKET (2021) 62
5.6 PATENT ANALYSIS 64
5.6.1 PATENT PUBLICATION TRENDS FOR PARTICLE THERAPY MARKET 64
FIGURE 24 GLOBAL PATENT PUBLICATION TRENDS IN PARTICLE THERAPY, 2016-2021 64
5.6.2 TOP APPLICANTS (COMPANIES) FOR PARTICLE THERAPY PATENTS 65
FIGURE 25 TOP COMPANIES THAT APPLIED FOR PARTICLE THERAPY PRODUCTS PATENTS, 2016–2021 65
5.6.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN PARTICLE THERAPY MARKET 65
FIGURE 26 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR PARTICLE THERAPY PATENTS, 2016–2021 65
5.7 VALUE CHAIN ANALYSIS 66
FIGURE 27 PARTICLE THERAPY MARKET: VALUE CHAIN ANALYSIS (2021) 66
5.8 TECHNOLOGY ANALYSIS 67
5.9 KEY CONFERENCES & EVENTS IN 2022-2023 67
5.10 REGULATORY LANDSCAPE 68
TABLE 3 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES 68
TABLE 4 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PARTICLE THERAPY PRODUCTS BY COUNTRY/REGION 69
5.11 PORTER’S FIVE FORCES ANALYSIS 70
TABLE 5 PARTICLE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 70
5.11.1 THREAT OF NEW ENTRANTS 70
FIGURE 28 THREAT OF NEW ENTRANTS 70
5.11.2 THREAT OF SUBSTITUTES 71
FIGURE 29 THREAT OF SUBSTITUTES 71
5.11.3 BARGAINING POWER OF SUPPLIERS 71
FIGURE 30 BARGAINING POWER OF SUPPLIERS 71
5.11.4 BARGAINING POWER OF BUYERS 72
FIGURE 31 BARGAINING POWER OF BUYERS 72
5.11.5 DEGREE OF COMPETITION 72
FIGURE 32 DEGREE OF COMPETITION 72

5.12 KEY STAKEHOLDERS & BUYING CRITERIA 73
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 73
FIGURE 33 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS
FOR TOP 3 APPLICATIONS 73
TABLE 6 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS
FOR TOP 3 APPLICATIONS (%) 73
5.12.2 BUYING CRITERIA 74
FIGURE 34 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS 74
TABLE 7 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS 74
6 PARTICLE THERAPY MARKET, BY TYPE 75
6.1 INTRODUCTION 76
TABLE 8 PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 76
6.2 PROTON THERAPY 76
6.2.1 PROTON THERAPY TO BE INCREASINGLY ADOPTED AS PRIMARY TREATMENT MODE FOR VARIOUS CANCER TYPES 76
TABLE 9 PARTICLE THERAPY MARKET FOR PROTON THERAPY,
BY COUNTRY, 2020–2027 (USD MILLION) 77
6.3 HEAVY ION THERAPY 77
6.3.1 USE OF HEAVY ION THERAPY TO BE STILL IN EXPERIMENTAL PHASE ACROSS MANY REGIONS 77
TABLE 10 PARTICLE THERAPY MARKET FOR HEAVY ION THERAPY, BY COUNTRY,
2020–2027 (USD MILLION) 78
7 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE 79
7.1 INTRODUCTION 80
TABLE 11 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 80
7.2 PRODUCTS 80
TABLE 12 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE,
2020–2027(USD MILLION) 80
TABLE 13 PARTICLE THERAPY PRODUCT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 81
7.3 CYCLOTRONS 81
7.3.1 INCREASED MANUFACTURING BY LEADING PLAYERS IN PARTICLE THERAPY TO PROPEL MARKET GROWTH 81
TABLE 14 PARTICLE THERAPY CYCLOTRONS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 82
7.4 SYNCHROTRONS 82
7.4.1 INCREASING INVESTMENTS FOR DEVELOPMENT FACILITIES
TO AID MARKET GROWTH 82
TABLE 15 PARTICLE THERAPY SYNCHROTRONS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 83
7.5 SYNCHROCYCLOTRON 83
7.5.1 HIGH SPACE REQUIREMENTS TO LIMIT WIDESPREAD ADAPTION 83
TABLE 16 PARTICLE THERAPY SYNCHROCYCLOTRON MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 84
7.6 SERVICES 84
TABLE 17 PARTICLE THERAPY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
8 PARTICLE THERAPY MARKET, BY SYSTEM 86
8.1 INTRODUCTION 87
TABLE 18 PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION) 87
8.2 MULTI-ROOM SYSTEMS 87
8.2.1 LOWER SHIELDING REQUIREMENTS AND FASTER BEAM-SWITCHING CAPABILITIES TO DRIVE INTEREST AMONG END USERS 87
TABLE 19 PARTICLE THERAPY MARKET FOR MULTI-ROOM SYSTEMS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
8.3 SINGLE-ROOM SYSTEMS 88
8.3.1 COMPACT STRUCTURE AND REDUCED CAPITAL COSTS
TO PROPEL SEGMENT GROWTH 88
TABLE 20 PARTICLE THERAPY MARKET FOR SINGLE ROOM SYSTEM, BY COUNTRY, 2020–2027 (USD MILLION) 89
9 PARTICLE THERAPY MARKET, BY CANCER TYPE 90
9.1 INTRODUCTION 91
TABLE 21 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION) 91
9.2 PEDIATRIC CANCER 91
9.2.1 BETTER CONTROL OF RADIATION WITH PARTICLE THERAPY TO POPULARIZE THIS TREATMENT MODE 91
TABLE 22 PARTICLE THERAPY MARKET FOR PEDIATRIC CANCER, BY COUNTRY,
2020–2027 (USD MILLION) 92
9.3 PROSTATE CANCER 92
9.3.1 PARTICLE THERAPY TO OFFER MINIMALLY INVASIVE ALTERNATIVE WITH INCREASED ACCURACY 92
TABLE 23 PARTICLE THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY,
2020–2027 (USD MILLION) 93
9.4 LUNG CANCER 93
9.4.1 RISING NUMBER OF CLINICAL TRIALS TO OPTIMIZE PARTICLE THERAPY
TO DRIVE MARKET GROWTH 93
TABLE 24 PARTICLE THERAPY MARKET FOR LUNG CANCER, BY COUNTRY,
2020–2027 (USD MILLION) 94
9.5 BREAST CANCER 94
9.5.1 LIMITED RADIATION EXPOSURE WITH REDUCED SIDE-
EFFECTS TO INCREASE ADOPTION OF PARTICLE THERAPY 94
TABLE 25 PARTICLE THERAPY MARKET FOR BREAST CANCER, BY COUNTRY,
2020–2027 (USD MILLION) 95
9.6 HEAD & NECK CANCER 95
9.6.1 USE OF PENCIL-BEAM SCANNING FOR PROTON THERAPY
TO SUPPORT SEGMENT GROWTH 95
TABLE 26 PARTICLE THERAPY MARKET FOR HEAD AND NECK CANCER,
BY COUNTRY, 2020–2027 (USD MILLION) 96
9.7 OTHER CANCERS 96
TABLE 27 PARTICLE THERAPY MARKET FOR OTHER CANCERS,
BY COUNTRY, 2020–2027 (USD MILLION) 97
10 PARTICLE THERAPY MARKET, BY APPLICATION 98
10.1 INTRODUCTION 99
TABLE 28 PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 99
10.2 TREATMENT APPLICATIONS 99
10.2.1 INTRODUCTION OF SMALL FOOTPRINT SINGLE-ROOM PARTICLE THERAPY CENTERS TO PROMOTE PARTICLE THERAPY FOR CANCER TREATMENT 99
TABLE 29 PARTICLE THERAPY MARKET FOR TREATMENT APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 100
10.3 RESEARCH APPLICATIONS 100
10.3.1 INCREASING AVAILABILITY OF FUNDING FOR PARTICLE THERAPY-RELATED RESEARCH PROJECTS TO PROVIDE GROWTH OPPORTUNITIES 100
TABLE 30 PARTICLE THERAPY MARKET FOR RESEARCH APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 101
11 PARTICLE THERAPY MARKET, BY REGION 102
11.1 INTRODUCTION 103
FIGURE 35 CHINA TO DOMINATE PARTICLE THERAPY
MARKET DURING FORECAST PERIOD 103
TABLE 31 PARTICLE THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 103
TABLE 32 PARTICLE THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 104
11.2 NORTH AMERICA 104
FIGURE 36 NORTH AMERICA: PARTICLE THERAPY MARKET SNAPSHOT 105
TABLE 33 NORTH AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 105
TABLE 34 NORTH AMERICA: PARTICLE THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 106
TABLE 35 NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 106
TABLE 36 NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 106
TABLE 37 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 107
TABLE 38 NORTH AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 107
TABLE 39 NORTH AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 107
11.2.1 US 108
11.2.1.1 Growing number of particle therapy centers to drive market growth 108
TABLE 40 US: MACROECONOMIC INDICATORS 108
TABLE 41 US: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 42 US: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 109
TABLE 43 US: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 109
TABLE 44 US: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION) 110
TABLE 45 US: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 110
TABLE 46 US: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 110
11.2.2 CANADA 111
11.2.2.1 Canadian government to initiate inclusion of particle therapy as treatment method 111
TABLE 47 CANADA: MACROECONOMIC INDICATORS 111
TABLE 48 CANADA: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 49 CANADA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 112
TABLE 50 CANADA: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 112
TABLE 51 CANADA: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 113
TABLE 52 CANADA: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 113
TABLE 53 CANADA: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 113
11.3 EUROPE 114
FIGURE 37 EUROPE: PARTICLE THERAPY MARKET SNAPSHOT 115
TABLE 54 EUROPE: PARTICLE THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 116
TABLE 55 EUROPE: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 56 EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 116
TABLE 57 EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 117
TABLE 58 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 117
TABLE 59 EUROPE: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 117
TABLE 60 EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 118
11.3.1 GERMANY 118
11.3.1.1 Increasing research in proton and heavy ion therapy
to drive market growth 118
TABLE 61 GERMANY: MACROECONOMIC INDICATORS 118
TABLE 62 GERMANY: PARTICLE THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 119
TABLE 63 GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 119
TABLE 64 GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 119
TABLE 65 GERMANY: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 120
TABLE 66 GERMANY: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 120
TABLE 67 GERMANY: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 120
11.3.2 FRANCE 121
11.3.2.1 Increasing healthcare expenditure to support particle therapy products adoption 121
TABLE 68 FRANCE: MACROECONOMIC INDICATORS 121
TABLE 69 FRANCE: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 70 FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 122
TABLE 71 FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 122
TABLE 72 FRANCE: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 123
TABLE 73 FRANCE: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 123
TABLE 74 FRANCE: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 123
11.3.3 UK 124
11.3.3.1 Cyclotrons segment to dominate market growth 124
TABLE 75 UK: MACROECONOMIC INDICATORS 124
TABLE 76 UK: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 77 UK: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 125
TABLE 78 UK: PARTICLE THERAPY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 125
TABLE 79 UK: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION) 126
TABLE 80 UK: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 126
TABLE 81 UK: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 126
11.3.4 ITALY 127
11.3.4.1 Increasing awareness activities to support market growth 127
TABLE 82 ITALY: MACROECONOMIC INDICATORS 127
TABLE 83 ITALY: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 84 ITALY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 128
TABLE 85 ITALY: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 128
TABLE 86 ITALY: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION) 128
TABLE 87 ITALY: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 129
TABLE 88 ITALY: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 129
11.3.5 SPAIN 129
11.3.5.1 Increasing number of conferences and government funding for cancer research to drive market growth 129
TABLE 89 SPAIN: MACROECONOMIC INDICATORS 131
TABLE 90 SPAIN: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 91 SPAIN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 131
TABLE 92 SPAIN: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 132
TABLE 93 SPAIN: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION) 132
TABLE 94 SPAIN: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 132
TABLE 95 SPAIN: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 133
11.3.6 REST OF EUROPE 133
TABLE 96 REST OF EUROPE: PARTICLE THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 133
TABLE 97 REST OF EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 134
TABLE 98 REST OF EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 134
TABLE 99 REST OF EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 134
TABLE 100 REST OF EUROPE: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 135
TABLE 101 REST OF EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
11.4 ASIA PACIFIC 135
FIGURE 38 ASIA PACIFIC: PARTICLE THERAPY MARKET SNAPSHOT 136
TABLE 102 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 137
TABLE 103 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 137
TABLE 104 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 137
TABLE 105 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 138
TABLE 106 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 138
TABLE 107 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 138
TABLE 108 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 139
11.4.1 JAPAN 139
11.4.1.1 Increasing use of heavy ion therapy for cancer treatment
to propel market growth 139
TABLE 109 JAPAN: MACROECONOMIC INDICATORS 140
TABLE 110 JAPAN: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 111 JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 140
TABLE 112 JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 141
TABLE 113 JAPAN: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 141
TABLE 114 JAPAN: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 141
TABLE 115 JAPAN: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 142
11.4.2 CHINA 142
11.4.2.1 Growing interest of major market players to increase their presence to drive market growth 142
TABLE 116 CHINA: MACROECONOMIC INDICATORS 143
TABLE 117 CHINA: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 118 CHINA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 143
TABLE 119 CHINA: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 144
TABLE 120 CHINA: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 144
TABLE 121 CHINA: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 144
TABLE 122 CHINA: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 145
11.4.3 INDIA 145
11.4.3.1 Leading product manufacturers with high growth opportunities to propel market growth 145
TABLE 123 INDIA: MACROECONOMIC INDICATORS 145
TABLE 124 INDIA: PARTICLE THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 125 INDIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 146
TABLE 126 INDIA: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 146
TABLE 127 INDIA: PARTICLE THERAPY MARKET, BY SYSTEM, 2020–2027 (USD MILLION) 147
TABLE 128 INDIA: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 147
TABLE 129 INDIA: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 147
11.4.4 REST OF ASIA PACIFIC 148
TABLE 130 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 148
TABLE 131 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 148
TABLE 132 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 149
TABLE 133 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 149
TABLE 134 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION) 149
TABLE 135 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 150
11.5 LATIN AMERICA 150
11.5.1 LOW-COST SURGERIES TO DRIVE MEDICAL TOURISM 150
TABLE 136 LATIN AMERICA: PARTICLE THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 150
TABLE 137 LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 151
TABLE 138 LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 151
TABLE 139 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 151
TABLE 140 LATIN AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE,
2020–2027 (USD MILLION) 152
TABLE 141 LATIN AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 152
11.6 MIDDLE EAST & AFRICA 152
11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH 152
TABLE 142 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 143 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 153
TABLE 144 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 154
TABLE 145 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM,
2020–2027 (USD MILLION) 154
TABLE 146 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION) 154
TABLE 147 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 155
12 COMPETITIVE LANDSCAPE 156
12.1 OVERVIEW 156
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 156
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 157
12.4 MARKET SHARE ANALYSIS 158
12.5 COMPANY EVALUATION QUADRANT 159
FIGURE 41 PARTICLE THERAPY MARKET: COMPANY EVALUATION MATRIX, 2021 160
12.5.1 STARS 160
12.5.2 PERVASIVE PLAYERS 160
12.5.3 EMERGING LEADERS 161
12.5.4 PARTICIPANTS 161

12.6 COMPETITIVE BENCHMARKING 161
12.6.1 OVERALL COMPANY FOOTPRINT 161
TABLE 148 OVERALL COMPANY FOOTPRINT (13 COMPANIES) 161
TABLE 149 COMPANY FOOTPRINT: BY-TYPE (13 COMPANIES) 162
TABLE 150 COMPANY FOOTPRINT: BY PRODUCT & SERVICES (13 COMPANIES) 163
TABLE 151 COMPANY FOOTPRINT: BY SYSTEM (13 COMPANIES) 164
TABLE 152 COMPANY FOOTPRINT: BY CANCER TYPE (13 COMPANIES) 165
TABLE 153 COMPANY FOOTPRINT: BY APPLICATION (13 COMPANIES) 166
TABLE 154 COMPANY FOOTPRINT: BY REGION (13 COMPANIES) 167
12.7 COMPETITIVE SCENARIO 168
12.7.1 PRODUCT LAUNCHES & APPROVALS 168
12.7.2 DEALS 168
TABLE 155 DEALS 168
12.7.3 EXPANSIONS 170
TABLE 156 EXPANSIONS 170
13 COMPANY PROFILES 171
13.1 KEY PLAYERS 171
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 IBA WORLDWIDE 171
TABLE 157 IBA WORLDWIDE: BUSINESS OVERVIEW 171
FIGURE 42 IBA WORLDWIDE: COMPANY SNAPSHOT (2021) 172
13.1.2 VARIAN MEDICAL SYSTEMS, INC. 176
TABLE 158 VARIAN MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW 176
FIGURE 43 VARIAN MEDICAL SYSTEMS, INC: COMPANY SNAPSHOT (2021) 177
13.1.3 HITACHI LTD. 183
TABLE 159 HITACHI LTD.: BUSINESS OVERVIEW 183
FIGURE 44 HITACHI LTD.: COMPANY SNAPSHOT (2020) 184
13.1.4 MEVION MEDICAL SYSTEMS 186
TABLE 160 MEVION MEDICAL SYSTEMS: BUSINESS OVERVIEW 186
13.1.5 SUMITOMO HEAVY INDUSTRIES LTD. 189
TABLE 161 SUMITOMO HEAVY INDUSTRIES LTD.: BUSINESS OVERVIEW 189
FIGURE 45 SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY SNAPSHOT (2020) 190
13.1.6 PROVISION HEALTHCARE, LLC 192
TABLE 162 PROVISION HEALTHCARE, LLC: BUSINESS OVERVIEW 192
13.1.7 TOSHIBA MEDICAL SYSTEMS CORPORATION 193
TABLE 163 TOSHIBA MEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW 193
FIGURE 46 TOSHIBA MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2020) 194
13.1.8 OPTIVUS PROTON THERAPY, INC. 195
TABLE 164 OPTIVUS PROTON THERAPY, INC.: BUSINESS OVERVIEW 195
13.1.9 PROTOM INTERNATIONAL, INC. 196
TABLE 165 PROTOM INTERNATIONAL INC.: BUSINESS OVERVIEW 196
13.1.10 ADVANCED ONCOTHERAPY PLC. 197
TABLE 166 ADVANCED ONCOTHERAPY PLC.: BUSINESS OVERVIEW 197
13.2 OTHER PLAYERS 198
13.2.1 DANFYSIK A/S 198
TABLE 167 DANFYSIK A/S.: BUSINESS OVERVIEW 198
13.2.2 P-CUREA 199
TABLE 168 P-CURE: BUSINESS OVERVIEW 199
13.2.3 PTW FREIBURG GMBH 200
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 201
14.1 DISCUSSION GUIDE 201
14.2 INDUSTRY INSIGHTS 205
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 206
14.4 AVAILABLE CUSTOMIZATIONS 208
14.5 RELATED REPORTS 208
14.6 AUTHOR DETAILS 209

ページTOPに戻る

Table of Contents

Summary

MarketsandMarkets expects particle therapy market is projected to reach USD 1,004 million by 2027 from USD 677 million in 2022, growing at a CAGR of 8.2% from 2022 to 2027. Market growth is driven by factors such as the various advantages offered by the growing global prevalence of cancer, particle therapy advantages over photon therapy, increasing acceptance of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide. However, affordability & accessibility of treatments and infrastructural are expected to limit market growth to a certain extent in the coming years.
In this report, the particle therapy market is segmented on the basis of type, product and services, cancer type, application, cancer type, and region.
“Treatment Application accounted for the largest share in the particle therpy market by application type”
Based on applications, the particle therapy market has been segmented into treatment and research applications. In 2021, the treatment applications segment is projected to account for the dominant share of 94.4% of the particle therapy market. Increasing government initiatives aimed at equipping or upgrading hospitals with newer and advanced radiotherapy systems.

“Proton Therapy accounted for the largest share in the particle therpy market by type”

On the basis of type, the particle therapy market is segmented into proton therapy and heavy ion therapy. The proton therapy segment is expected to account for the largest share (85.7%) of the market in 2021. Factors such as the high dose of radiation, shorter treatment time, a high degree of precision, and lowered side effects as compared to conventional photon therapies using traditional X-rays.

“Based on product, cyclotrons accounted for the largest share in the particle therpy market”

Based on product, the particle therapy products market is further segmented into cyclotrons, synchrotrons, and synchrocyclotrons. In 2021, the cyclotrons segment is expected to account for a share of 71.4% of the particle therapy market; this segment is projected to grow at a CAGR of 6.7% during the forecast period. Advantages offered by cyclotrons over other accelerators and the development of technologically advanced systems are the major factors pushing the development of this market segment.

“Asia Pacific segment accounted for the largest share in the particle therapy market by Region”
The Asia Pacific market is expected to account for the largest market share in 2021 and is also projected to witness the highest growth rate during the forecast period. The Asia Pacific region is expected to offer significant growth opportunities for players operating in the particle therapy market owing to the increasing healthcare expenditure and growing initiatives to promote the use of advanced particle therapy technologies in the Asia Pacific countries.

Key Market Players :
Prominent players in the particle therapy market include IBA Worldwide (EU), Hitachi, Ltd. (Japan), Varian Medical Systems, Inc. (US), Provision Healthcare, LLC (US), Optivus Proton Therapy, Inc. (US), and Protom International, Inc. (US).
A breakdown of the primary participants (supply-side) for the particle therapy market referred to for this report is provided below:
• By Company Type: Tier 1–5%, Tier 2–15%, and Tier 3–80%
• By Designation: C-level–45%, Director Level–25%, and Others–30%
• By Region: North America–36%, Europe–26%, Asia Pacific–21%, Latin America- 10%, and Middle East and Africa– 7%
Research Coverage:
The market study covers the particle therapy market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by product, by application, by end user, and by region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information regarding the closest approximations of the particle therapy market and its segments. This report will help stakeholders understand the competitive landscape, gain insights to position their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders in understanding the pulse of the market and gaining information on key market drivers, restraints, opportunities, and challenges.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（プライマリケア）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（cancer）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（プライマリケア）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（cancer）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?